Clinical Trials

GastrointestinalGenitourinaryThoracic

50 enrolled

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Kidney Neoplasms, Stomach Neoplasms

NCT06052306 2026-04-17

A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

Phase 1 Active not recruiting

232 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT06353386 2026-04-17

MK-5684-01A

220 enrolled

Phase 1 Active not recruiting

Prostatic Neoplasms, Castration-Resistant

NCT06545942 2026-04-17

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

220 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT06760702 2026-04-17

TEJAS-2

Phase 2 Terminated

29 enrolled

GastrointestinalGenitourinaryGynecologic

Kidney Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT07114601 2026-04-17

OMNIRAY

BreastGastrointestinalGenitourinaryGynecologic

421 enrolled

Breast Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT07218380 2026-04-17

FORAGER-2

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT07222488 2026-04-17

MK-3120-003

45 enrolled

Urinary Bladder Neoplasms

NCT07227402 2026-04-17

LITESPARK-033

904 enrolled

Carcinoma, Carcinoma, Renal Cell

NCT07405164 2026-04-17

MK-6482-043

Phase EARLY_PHASE1 Recruiting

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT07468708 2026-04-17

The Dosimetry, Safety and Diagnostic Efficacy of ⁶⁸Ga-FC516 in Healthy Subjects and Patients With Prostate Cancer

30 enrolled

Prostatic Neoplasms

NCT05939414 2026-04-16

PSMA-DC

Phase NA Active not recruiting

Oligometastatic Prostate Cancer (OMPC)

NCT06451614 2026-04-16

HYDROSPACE

230 enrolled

Prostatic Neoplasms

NCT06629779 2026-04-16

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

900 enrolled

Metastatic Castration-Resistant Prostate Cancer

NCT06780670 2026-04-16

PSMAcTION

Phase 2/3 Recruiting

443 enrolled

Prostatic Neoplasms

NCT06991556 2026-04-16

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Phase 2 Recruiting

150 enrolled

Metastatic Hormone-sensitive Prostate Cancer

NCT07206056 2026-04-16

TulmiSTAR-01

188 enrolled

Progressive Metastatic Castrate Resistant Prostate Cancer

NCT07213674 2026-04-16

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

750 enrolled

Prostatic Neoplasms

NCT07226986 2026-04-16

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

123 enrolled

PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

NCT07416123 2026-04-16

A Study of GEN1106 in Participants With Solid Tumors

103 enrolled

Carcinoma, Transitional Cell

NCT03661320 2026-04-15

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

855 enrolled

Phase 4 Active not recruiting

Urinary Bladder Neoplasms

NCT04597125 2026-04-15

RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

654 enrolled

Phase NA Active not recruiting

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

NCT04905069 2026-04-15

SABRE

500 enrolled

GenitourinaryGynecologicThoracic

Neoplasms, Prostatic Neoplasms

NCT05397093 2026-04-15

ITIL-306 in Advanced Solid Tumors

Phase 1 Terminated

1 enrolled

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms

NCT05483868 2026-04-15

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

55 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT05581004 2026-04-15

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms

NCT06010914 2026-04-15

DADOX

Active not recruiting

100 enrolled

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT06136650 2026-04-15

MK-5684-004

1,314 enrolled

Phase 2/3 Active not recruiting

Prostatic Neoplasms

NCT06225596 2026-04-15

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

956 enrolled

Urinary Bladder Neoplasms

NCT06511141 2026-04-15

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

Phase NA Recruiting

150 enrolled

Prostatic Hyperplasia, Prostatic Neoplasms, Urinary Bladder, Overactive

NCT07106762 2026-04-15

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

Phase 2/3 Recruiting

470 enrolled

Urinary Bladder Neoplasms

NCT07223372 2026-04-15

TARA

Recruiting

1,000 enrolled

Phase 1 Active not recruiting

Metastatic Hormonesensitive Prostate Cancer (mHSPC)

NCT07236112 2026-04-15

Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Prostate Cancer

6 enrolled

Prostatic Neoplasms

NCT07475806 2026-04-15

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

Phase 2 Recruiting

240 enrolled

Phase 1 Not yet recruiting

Muscle-invasive Bladder Cancer

NCT07518043 2026-04-15

A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors

174 enrolled

DermatologicGenitourinary

Carcinoma, Transitional Cell, Melanoma

NCT03091192 2026-04-14

Savolitinib vs. Sunitinib in MET-driven PRCC.

60 enrolled 15 charts

Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms by Site, Urologic Neoplasms

NCT03528694 2026-04-14

POTOMAC

1,018 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT04122976 2026-04-14

DAROL

Active not recruiting

805 enrolled

Prostatic Neoplasms

NCT04960709 2026-04-14

VOLGA

712 enrolled

Urinary Bladder Neoplasms

NCT05847166 2026-04-14

A Phase 2/3,PSMA-T4, Prostate Cancer

Phase NA Recruiting

80 enrolled

Prostatic Neoplasms

NCT06011954 2026-04-14

A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection

Recruiting

202 enrolled

Urinary Bladder Neoplasms

NCT06026410 2026-04-14

FIT-001